Marie-Françoise Ben Dridi

Learn More
Nizar Ben Halim & Nissaf Ben Alaya Bouafif & Lilia Romdhane & Rym Kefi Ben Atig & Ibtissem Chouchane & Yosra Bouyacoub & Imen Arfa & Wafa Cherif & Sonia Nouira & Faten Talmoudi & Khaled Lasram & Sana Hsouna & Welid Ghazouani & Hela Azaiez & Leila El Matri & Abdelmajid Abid & Neji Tebib & Marie-Françoise Ben Dridi & Salem Kachboura & Ahlem Amouri & Mourad(More)
Type 1 Gaucher disease (GD1), resulting from glucocerebrosidase deficiency, leads to splenomegaly, hepatomegaly, anemia, thrombocytopenia, and bone involvement. Current standard treatment is enzyme replacement therapy. Velaglucerase alfa is an enzyme replacement product for GD1, with the same amino acid sequence as naturally occurring human(More)
Hereditary C1q deficiency (C1qD) is the most penetrant genetic factor predisposing to the development of lupus pathology with more than 93% of C1q deficient patients developing this autoimmune pathology throughout their life. It is a rare autosomal recessive deficiency, with only 67 cases reported so far including one Tunisian girl who died at the age of(More)
Genetic deficiency of the glycogen debranching enzyme causes glycogen storage disease type III, an autosomal recessive inherited disorder. The gene encoding this enzyme is designated as AGL gene. The disease is characterized by fasting hypoglycemia, hepatomegaly, growth retardation, progressive myopathy and cardiomyopathy. In the present study, we present(More)
Glycogen storage disease type III (GSD III; Cori disease; Forbes disease) is an autosomal recessive inherited metabolic disorder resulting from deficient glycogen debrancher enzyme activity in liver and muscle. In this study, we focused on a single AGL gene mutation p.W1327X in 16 Tunisian patients from rural area surrounding the region of Mahdia in Central(More)
  • 1